{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Numerical+label&page=2", "query": { "intervention": "Numerical label", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Numerical+label&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-16T21:04:16.247Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02368951", "title": "Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Medical Oncology" ], "interventions": [ { "name": "BAY1187982", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2015-03-24", "completion_date": "2016-07-27", "has_results": false, "last_update_posted_date": "2017-07-12", "last_synced_at": "2026-09-16T21:04:16.247Z", "location_count": 10, "location_summary": "San Francisco, California • Santa Monica, California • New Haven, Connecticut + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02368951" }, { "nct_id": "NCT02200757", "title": "Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Small Cell Lung Cancer" ], "interventions": [ { "name": "Aldoxorubicin", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 135, "start_date": "2015-04-20", "completion_date": "2017-05-15", "has_results": true, "last_update_posted_date": "2024-06-25", "last_synced_at": "2026-09-16T21:04:16.247Z", "location_count": 11, "location_summary": "Los Angeles, California • Pasadena, California • Fleming Island, Florida + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Fleming Island", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT02200757" }, { "nct_id": "NCT02674750", "title": "Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations" ], "interventions": [ { "name": "CUDC-907", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Curis, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2016-07", "completion_date": "2019-05-28", "has_results": true, "last_update_posted_date": "2022-04-27", "last_synced_at": "2026-09-16T21:04:16.247Z", "location_count": 20, "location_summary": "Fresno, California • Los Angeles, California • Tampa, Florida + 15 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02674750" }, { "nct_id": "NCT00803387", "title": "Dry Eye and Irritation Comparison of Latanoprost With the Preservative Versus Travoprost Without Preservative", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Ocular Dryness", "Ocular Irritation", "Open-Angle Glaucoma", "Ocular Hypertension" ], "interventions": [ { "name": "Travaprost without BAC (Travatan Z)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "United States Air Force", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 33, "start_date": "2008-04", "completion_date": "2008-09", "has_results": false, "last_update_posted_date": "2008-12-05", "last_synced_at": "2026-09-16T21:04:16.247Z", "location_count": 1, "location_summary": "Lackland Air Force Base, Texas", "locations": [ { "city": "Lackland Air Force Base", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00803387" }, { "nct_id": "NCT04264026", "title": "MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Post Traumatic Stress Disorder", "Combat Stress Disorders" ], "interventions": [ { "name": "3,4-methylenedioxymethamphetamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VA Loma Linda Health Care System", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 5, "start_date": "2021-07-29", "completion_date": "2025-05-01", "has_results": false, "last_update_posted_date": "2025-07-20", "last_synced_at": "2026-09-16T21:04:16.247Z", "location_count": 1, "location_summary": "Loma Linda, California", "locations": [ { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04264026" }, { "nct_id": "NCT01564784", "title": "A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "inotuzumab ozogamicin", "type": "DRUG" }, { "name": "FLAG (fludarabine, cytarabine and G-CSF)", "type": "DRUG" }, { "name": "HIDAC (high dose cytarabine)", "type": "DRUG" }, { "name": "cytarabine and mitoxantrone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 326, "start_date": "2012-08-02", "completion_date": "2017-01-04", "has_results": true, "last_update_posted_date": "2019-01-09", "last_synced_at": "2026-09-16T21:04:16.247Z", "location_count": 96, "location_summary": "La Jolla, California • Los Angeles, California • Orange, California + 39 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01564784" }, { "nct_id": "NCT01379209", "title": "Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Graft Versus Host Disease" ], "interventions": [ { "name": "RGI-2001", "type": "DRUG" }, { "name": "Calcineurin Inhibitors", "type": "DRUG" }, { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Conditioning Regimen", "type": "DRUG" }, { "name": "Allogeneic Bone Marrow Transplantation", "type": "PROCEDURE" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Mofetil Mycophenolate", "type": "DRUG" }, { "name": "sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Regimmune Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2011-09", "completion_date": "2017-04", "has_results": false, "last_update_posted_date": "2019-10-23", "last_synced_at": "2026-09-16T21:04:16.247Z", "location_count": 6, "location_summary": "San Diego, California • Stanford, California • Tampa, Florida + 3 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Columbus", "state": "Ohio" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01379209" }, { "nct_id": "NCT04050709", "title": "QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Solid Tumor", "Metastatic Cancer", "Solid Tumor" ], "interventions": [ { "name": "PD-L1 t-haNK", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2019-07-18", "completion_date": "2026-03-25", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-09-16T21:04:16.247Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04050709" }, { "nct_id": "NCT04879849", "title": "A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Triple Negative Breast Neoplasms", "Squamous Cell Carcinoma of Head and Neck" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "TAK-676", "type": "DRUG" }, { "name": "Image-guided radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2021-09-09", "completion_date": "2024-04-30", "has_results": true, "last_update_posted_date": "2025-09-04", "last_synced_at": "2026-09-16T21:04:16.247Z", "location_count": 5, "location_summary": "Duarte, California • Chicago, Illinois • New York, New York + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04879849" }, { "nct_id": "NCT05775159", "title": "Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma", "Biliary Tract Cancer" ], "interventions": [ { "name": "Volrustomig", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 294, "start_date": "2023-04-24", "completion_date": "2027-10-28", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-09-16T21:04:16.247Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05775159" } ] }